{{Rsnum
|rsid=9878473
|Gene=GSK3B
|Chromosome=3
|position=119931941
|Orientation=plus
|GMAF=0.4504
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=GSK3B
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 8.8 | 47.8 | 43.4
| HCB | 24.1 | 55.5 | 20.4
| JPT | 32.7 | 45.1 | 22.1
| YRI | 97.3 | 2.7 | 0.0
| ASW | 68.4 | 29.8 | 1.8
| CHB | 24.1 | 55.5 | 20.4
| CHD | 31.2 | 51.4 | 17.4
| GIH | 27.7 | 47.5 | 24.8
| LWK | 90.9 | 9.1 | 0.0
| MEX | 8.6 | 51.7 | 39.7
| MKK | 57.7 | 37.2 | 5.1
| TSI | 13.7 | 56.9 | 29.4
| HapMapRevision=28
}}{{PMID Auto
|PMID=20605420
|Title=Association study of the GSK-3B gene with tardive dyskinesia in European Caucasians
}}

{{PMID Auto
|PMID=18676680
|Title=Pathway-based evaluation of 380 candidate genes and lung cancer susceptibility suggests the importance of the cell cycle pathway.
|OA=1
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | Illumina Human 1M}}